City Therapeutics EBIT

City Therapeutics (CTY) currently reports a EBIT of $2.2B as of June 2020. That compares with $2.8B in the prior-year period — down 21.3% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore City Therapeutics's EBIT history and peer comparisons.

City Therapeutics's EBIT decreased from $2.8B to $2.2B — a 21.3% year-over-year decrease (period ending June 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

City Therapeutics's EBIT of $2.2B is lower than the Healthcare sector average of $130B. That is roughly 98.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

City Therapeutics reported $2.2B in EBIT as of June 2020. That compares with $2.8B in the prior-year period — down 21.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $2.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for City Therapeutics, and consider following CTY for alerts when major investors trade the stock.